A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. 1997

R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
Department of Internal Medicine, University of Iowa College of Medicine, University of Iowa Hospitals and Clinics Iowa City, USA.

The management of hormone-refractory metastatic prostate cancer remains a therapeutic dilemma. We report the results of a phase II trial with deferoxamine administrated at a dose of 50 mg/kg (maximum dose 5 g) administered intravenously over 8 hr daily, repeated for 5 days at 4-week intervals for 2 courses. Fourteen patients with advanced hormone-refractory prostate cancer were treated and 28 courses were delivered. Essentially no toxicity was observed. Using combined clinical and prostate-specific antigen (PSA) criteria. 13 of 14 patients had disease progression. However, 9 of 14 patients had stable measurable or evaluable disease and progressed solely based on PSA criteria. Deferoxamine in this dose and schedule has no activity in hormone-refractory prostate cancer. Further investigation of the effect of deferoxamine on PSA production/expression is warranted.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008762 Methylhistidines Histidine substituted in any position with one or more methyl groups. Methylhistidine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010388 Pelvis The space or compartment surrounded by the pelvic girdle (bony pelvis). It is subdivided into the greater pelvis and LESSER PELVIS. The pelvic girdle is formed by the PELVIC BONES and SACRUM. Pelvic Region,Region, Pelvic
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine

Related Publications

R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
October 2007, BJU international,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
December 2008, Clinical cancer research : an official journal of the American Association for Cancer Research,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
September 2005, Clinical prostate cancer,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
January 1999, Cancer chemotherapy and pharmacology,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
April 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
January 1998, Investigational new drugs,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
September 1994, Urology,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
January 1998, Investigational new drugs,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
January 1995, Investigational new drugs,
R Dreicer, and J D Kemp, and L D Stegink, and T Cardillo, and C S Davis, and P K Forest, and W A See
August 2005, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!